Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Axios on your phone

Get breaking news and scoops on the go with the Axios app.

Download for free.

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Aïda Amer/Axios

Open-source the vaccines. That's the message being sent by the People's Vaccine Alliance, a coalition that includes Amnesty International, Oxfam, and UNAIDS.

Why it matters: Manufacturing capacity needs to be scaled up dramatically — and cutting out the need for laborious, expensive and secretive negotiations with vaccine patent holders could help.

What they're saying: "None of the manufacturers today are remotely capable of meeting demand on a timely basis," says Knowledge Ecology International's Jamie Love. "Vaccine manufacturers are currently hoarding technology, for commercial reasons."

By the numbers:  Of the 108 million people vaccinated so far, only 4% have been in developing countries.

  • Of the 108 million people vaccinated so far, only 4% have been in developing countries. Nearly all of those have been in India, where Oxford University ensured that the Serum Institute of India would be licensed to produce its vaccine at the same time that AstraZeneca received control of the intellectual property.
  • The global economy will lose $9 trillion if the developing world fails to receive timely access to vaccines, according to a study from the International Chamber of Commerce. Half of that cost will fall on rich countries.
  • According to the Alliance, there are at least 20 more facilities in India alone that could start producing vaccine, and many more in other countries such as Argentina, South Africa, Brazil, Mexico, and Indonesia.

The big picture: While Operation Warp Speed helped to stand up new manufacturing facilities in the U.S., there has been little to no such investment in most of the rest of the world.

  • "We need to build new capacity," says Oxfam's Niko Lusiani. "Even if it takes two years it will still be useful. For COVID-19, for future pandemics, and for future strains."
  • "Freeing up IP will unlock a lot of public and private investment into vaccine production."

Pfizer CFO Frank D'Amelio said on the company's earnings call this month that while "pandemic pricing" in the U.S. is $19.50 per dose, "a normal price that we typically get for a vaccine" would be $150 to $175 per dose.

  • The pandemic pricing gives Pfizer a profit margin of well over 20% — but D'Amelio said that "there's a significant opportunity for those margins to improve once we get beyond the pandemic environment" — when pricing will free up and factories become more efficient.

How it works: While international trade law does allow countries to overrule patent protection for vaccines, countries tend to be very reluctant to do so, because they fear retaliation and also because they need help with the technical knowhow involved in manufacturing the vaccines.

The other side: Opening up manufacturing to a point where the patent holders have no oversight could lead to quality-control issues.

  • Opponents of open-sourcing vaccines also say there's no evidence that there's a lot of spare manufacturing capacity.
  • China and Russia are also big unknowns. Both of them are likely to try to distribute their vaccines globally as a form of soft power.

Editor’s note: An earlier version of this article incorrectly attributed COVID-19 manufacturing capacity statistics to the wrong set of manufacturers.

Go deeper

Feb 14, 2021 - Health

Study on Pfizer vaccine shows 94% drop in symptomatic COVID-19 cases

Illustration: Brendan Lynch/Axios

A recent study by Israel’s largest healthcare provider found that after both doses of the Pfizer vaccine, people are 94% less likely to have symptomatic COVID-19 infections and 92% fewer cases of severe illness due to the virus, Reuters reports.

Why it matters: Israel has been rapidly vaccinating its population, and the new study underscores how effective the vaccine is, as the data nearly matches Pfizer's Phase three clinical trial that showed the vaccine to be 95% effective.

Feb 14, 2021 - World

China accuses U.S. of "pointing fingers" over COVID probe

Photo: Andrew Harrer/Bloomberg via Getty Images

China on Sunday accused the U.S. of "pointing fingers," following a statement from the Biden administration alleging that Beijing may have meddled into the World Health Organization's probe into the origins of the COVID-19 pandemic.

What they're saying: "What the U.S. has done in recent years has severely undermined multilateral institutions, including the WHO," China wrote in a statement from its embassy in D.C. It added that the U.S. has "gravely damaged international cooperation on COVID-19."